Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caralluma fimbriata extract is a dietary supplement derived from the edible cactus *Caralluma fimbriata*, native to India and traditionally used as a famine food and appetite suppressant. The extract contains various bioactive compounds including pregnane glycosides, flavonoids, saponins, phenolic compounds, and other phytochemicals[6][8][10]. It is primarily marketed for weight management due to its purported ability to suppress appetite—possibly through modulation of hypothalamic ATP content in neurons—and reduce waist circumference[1][4][7]. Some studies suggest it may help decrease hunger levels and waist size but show limited or no significant effect on overall body weight or BMI[3][4][5]. Additional research has explored potential antidiabetic, antioxidant, anti-inflammatory, hypolipemic (lipid-lowering), hepatoprotective (liver-protecting), and anticancer properties[6][9]. The U.S. FDA recognizes it as Generally Recognized As Safe (GRAS) for use in foods[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caralluma fimbriata extract.